Full Length ArticleEffect of the lipoxygenase-inhibitors baicalein and Zileuton (cas 111406-87-2) on the vertebra in ovariectomized rats

Add time:09/01/2019    Source:sciencedirect.com

Osteoporosis is one of the most common diseases worldwide. In osteoporosis, vertebral fractures represent a major burden. Lipoxygenase (LOX) inhibitors such as baicalein and Zileuton (cas 111406-87-2) may represent a promising therapeutic option owing to their antioxidative effects and suppression of various inflammatory processes in muscle and bone. The effect of these LOX inhibitors on the spine was studied in osteopenic rats.Female Sprague-Dawley rats were divided two times into five groups: four groups each were ovariectomized (OVX) and one control group was non-ovariectomized (NON-OVX). Eight weeks after ovariectomy, three concentrations of baicalein (1 mg/kg body weight [BW], 10 mg/kg BW, and 100 mg/kg BW) were administered subcutaneously daily in three OVX groups for 4 weeks. Similarly, zileuton was administered in three concentrations via food for 5 weeks. In vivo computed tomography (pQCT) of the spine was performed before the treatments and at the end of the experiment. Lumbar vertebrae were subjected to a compression test, micro-CT, and ashing analyses.After baicalein treatment, cortical bone mineral density (BMD) was improved; trabecular connectivity and trabecular BMD were diminished at high dose. After zileuton treatment, the total BMD, anorganic weight, trabecular nodes, and trabecular area were improved.The in vivo stress-strain index was increased and alkaline phosphatase activity in serum was enhanced after both treatments. A dose-dependent effect was not clearly observed after both treatments. The treatments using baicalein for 4 and zileuton for 5 weeks were not sufficient to change the biomechanical properties and bone volume fraction (BV/TV).Overall, baicalein improved the cortical bone parameters whereas zileuton had a favorable effect on the trabecular structure. Moreover, both treatments increased the bone formation rate. Longer trials, a combination of both LOX inhibitors, and their effect at the cellular and molecular levels should be investigated in further studies.

We also recommend Trading Suppliers and Manufacturers of Zileuton (cas 111406-87-2). Pls Click Website Link as below: cas 111406-87-2 suppliers

Prev:Molecularly imprinted polymer based sensor for measuring of Zileuton (cas 111406-87-2): Evaluation as a modifier for carbon paste electrode in electrochemically recognition
Next:Original Research ArticleZileuton (cas 111406-87-2) alleviates acute cisplatin nephrotoxicity: Inhibition of lipoxygenase pathway favorably modulates the renal oxidative/inflammatory/caspase-3 axis)